Chronic Kidney Disease

Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function present for ≥3 months with implications for health, characterized by decreased glomerular filtration rate (GFR) and/or markers of kidney damage (albuminuria, urine abnormalities, imaging abnormalities, or biopsy findings). CKD represents one of the most prevalent chronic conditions in the United States and worldwide, affecting approximately 10-15% of the adult population, with higher prevalence in older adults (>60 years) and specific racial/ethnic minorities, particularly Hispanic Americans and African Americans. The disease is stratified into five stages based on GFR categories and the presence of kidney damage, with clinical significance ranging from increased cardiovascular risk at early stages to end-stage renal disease (ESRD) requiring renal replacement therapy. CKD is clinically important because it is both a major independent cardiovascular risk factor and a progressive condition that leads to ESRD, necessitating either dialysis or transplantation; moreover, early recognition and treatment can substantially slow progression and reduce cardiovascular morbidity and mortality. Understanding CKD pathophysiology, accurate staging, and evidence-based management strategies are essential competencies for all physicians and represent high-yield examination material for board certification.

The pathophysiology of CKD involves a cascade of increasingly severe renal structural and functional changes that, once initiated by various primary or secondary insults, often progresses inexorably even if the original inciting cause is removed. The fundamental mechanism driving progression is nephron loss and subsequent maladaptive responses of remaining intact nephrons.

The primary insult (whether glomerular, tubular, interstitial, or vascular) causes direct damage to nephrons, leading to their functional loss and eventual fibrosis. In diabetic nephropathy, sustained hyperglycemia activates multiple pathways including the polyol pathway, advanced glycation end products (AGEs) formation, protein kinase C activation, and increased reactive oxygen species (ROS) production, all promoting glomerular basement membrane thickening and glomerulosclerosis. In hypertensive nephropathy, chronic elevation of intraglomerular pressure causes endothelial injury and progressive sclerosis. In IgA nephropathy and other primary glomerulonephropathies, immune complex deposition and complement activation trigger glomerular inflammation. In chronic obstructive nephropathy, sustained elevated tubular pressure leads to tubular atrophy and interstitial fibrosis. The degree of initial nephron loss determines the baseline GFR reduction and subsequent susceptibility to progression.

Once nephrons are lost, the remaining functional nephrons undergo compensatory hyperfiltration mediated by afferent arteriolar vasodilation (via prostaglandins and nitric oxide) and efferent arteriolar vasoconstriction (via angiotensin II), resulting in increased single-nephron GFR. While initially maintaining overall kidney function, this sustained elevation of intraglomerular capillary pressure (glomerular hypertension) perpetuates glomerular injury through mechanical stress on podocytes, increased proteinuria, and activation of pro-fibrotic pathways. This maladaptive response explains why progression may continue even after primary disease control (e.g., after blood pressure normalization or glycemic improvement in early diabetic disease).

Regardless of the initial insult, CKD progression converges on a final common pathway involving renal fibrosis, characterized by excessive deposition of extracellular matrix (collagen types I and III) in the glomeruli (glomerulosclerosis) and interstitium (interstitial fibrosis) with associated tubular atrophy. This is driven by several integrated mechanisms: (1) Epithelial-mesenchymal transition (EMT): tubular epithelial cells and glomerular podocytes undergo dedifferentiation and acquire mesenchymal characteristics, including expression of α-smooth muscle actin, facilitating migration into the interstitium where they differentiate into fibroblasts; (2) Activation of myofibroblasts: resident fibroblasts and pericytes become activated in response to injury signals (TGF-β, CTGF, angiotensin II) and proliferate, producing excessive collagen; (3) Activation of the renin-angiotensin-aldosterone system (RAAS): local and systemic angiotensin II production increases, stimulating myofibroblast activation, promoting EMT, increasing matrix production, and reducing matrix degradation through decreased matrix metalloproteinase (MMP) activity; (4) Inflammatory infiltration: recruitment of macrophages, T lymphocytes, and other immune cells releases pro-fibrotic cytokines including TGF-β, TNF-α, and interleukins; (5) Oxidative stress: accumulation of ROS from multiple sources (NADPH oxidase, mitochondrial dysfunction, uncoupled endothelial nitric oxide synthase) damages tubular and glomerular cells and directly promotes fibroblast activation. The interstitial fibrosis burden correlates strongly with GFR decline rate and eventual renal outcomes, making it a key pathological hallmark of CKD progression.

Albuminuria and proteinuria represent both markers of glomerular damage and independent contributors to progression. Proteinuria results from increased glomerular permeability due to podocyte injury and loss of the size and charge selectivity of the glomerular filtration barrier. The filtered proteins (particularly albumin and other larger proteins) are reabsorbed and catabolized by proximal tubular epithelial cells; however, excessive protein loads overwhelm reabsorptive capacity, leading to intracellular accumulation of proteins and activation of pro-inflammatory and pro-fibrotic intracellular pathways. Activation of protease-activated receptors (PARs), TLR4, and other receptors on tubular cells by filtered proteins induces NF-κB activation, ROS generation, and release of inflammatory mediators (monocyte chemoattractant protein-1, TNF-α) that recruit macrophages and perpetuate tubular-interstitial inflammation. Additionally, albumin-derived advanced glycation end products exert direct toxic effects on tubular cells.

As GFR falls, the kidney's capacity to maintain electrolyte and mineral balance is impaired. Phosphate retention occurs when GFR falls below ~60 mL/min/1.73m², leading to secondary hyperparathyroidism: retained phosphate directly suppresses 1,25-dihydroxyvitamin D [calcitriol] production by proximal tubules (via FGF23-mediated and direct mechanisms), reduces serum calcium, and stimulates parathyroid hormone (PTH) secretion. PTH initially maintains phosphate excretion by increasing urinary phosphate wasting per nephron, but as nephron number declines, this compensatory mechanism becomes insufficient. Sustained elevation of PTH (secondary hyperparathyroidism) contributes to renal osteodystrophy, vascular calcification, and cardiovascular mortality. FGF23 (fibroblast growth factor 23), a phosphaturic hormone produced by osteocytes in response to hyperphosphatemia, increases as an early compensatory mechanism but reaches very high levels in advanced CKD, directly causing cardiac hypertrophy and fibrosis independent of hemodynamic effects. Calcium homeostasis is disrupted by reduced renal production of calcitriol, reduced intestinal calcium absorption, and sequestration of calcium in tissue calcification sites. Potassium excretion is initially maintained through increased urinary potassium wasting per nephron and colonic secretion, but hyperkalemia develops as GFR declines below ~10-15 mL/min/1.73m² or with concurrent use of RAAS inhibitors, NSAIDs, or in patients with hypoaldosteronism.

Progressive loss of kidney mass reduces the kidney's capacity to excrete the daily acid load (~1 mEq/kg/day), leading to development of metabolic acidosis. This occurs through both decreased renal ammonia synthesis and reduced distal tubular hydrogen ion secretion. Metabolic acidosis has deleterious effects including protein catabolism (through activation of ubiquitin-proteasome and autophagy pathways), bone mineral loss (through buffering of acid with bone carbonate and phosphate), and worsening of hyperkalemia (through shifts of potassium out of cells in exchange for hydrogen ions).

As kidney function declines, the kidneys lose their ability to excrete the broad spectrum of water-soluble waste products generated by normal metabolism. Accumulation of these uremic toxins (including urea, creatinine, uric acid, phenolic compounds, guanidines, polyamines, and many others) produces the uremic syndrome. These toxins have direct toxic effects on vascular endothelium, cardiac myocytes, skeletal muscle, and the central nervous system; they also promote systemic inflammation, oxidative stress, and endothelial dysfunction, contributing substantially to the high cardiovascular morbidity and mortality in CKD.

CKD-associated anemia results primarily from decreased erythropoietin (EPO) production by renal fibroblasts due to loss of kidney mass and hypoxia-inducible factor dysfunction, combined with shortened red blood cell lifespan (from uremic toxins and chronic inflammation) and iron deficiency (from occult blood loss, reduced iron absorption, and chronic inflammation-induced hepcidin elevation). Anemia worsens tissue hypoxia, promotes cardiac compensation (tachycardia, increased cardiac output), and contributes to fatigue and cognitive impairment.

CKD is both a cause and consequence of hypertension through multiple mechanisms: sodium and fluid retention (from impaired renal excretion and activation of the sympathetic nervous system), activation of the RAAS, loss of renal vasodilatory factors (prostaglandins, nitric oxide, kinins), endothelial dysfunction, and increased vascular stiffness. Hypertension further accelerates nephron loss through glomerular hypertension and endothelial injury, creating a vicious cycle.

CKD results from diverse primary renal diseases and secondary systemic conditions affecting the kidney. The two most common causes globally—diabetes mellitus and hypertension—account for approximately 50-60% of all CKD cases in developed nations.

Diabetes is the leading cause of ESRD in most developed countries, accounting for 30-50% of incident dialysis patients. Diabetic nephropathy develops through the pathophysiological mechanisms described above, with hyperglycemia driving both hemodynamic changes (intraglomerular hypertension from preferential afferent arteriolar vasodilation) and metabolic changes (AGE formation, ROS production, TGF-β activation). Approximately 20-40% of type 1 diabetics and 10-20% of type 2 diabetics develop overt diabetic nephropathy; however, "non-albuminuric" diabetic CKD (reduced GFR without albuminuria) is increasingly recognized and may account for up to 30% of diabetic CKD cases. Risk factors for diabetic nephropathy include poor glycemic control (cumulative glucose exposure indexed by glycated hemoglobin), hypertension, genetic predisposition, and metabolic syndrome.

Chronic hypertension is the second leading cause of CKD and ESRD, accounting for 25-35% of cases. Hypertensive nephrosclerosis results from prolonged elevation of systemic and intraglomerular pressure causing arteriolar narrowing (hyaline arteriolosclerosis), glomerulosclerosis, and interstitial fibrosis. African Americans and other racial/ethnic minorities experience disproportionately higher rates of hypertensive kidney disease, reflecting both higher prevalence of hypertension and potentially increased genetic susceptibility. Uncontrolled or poorly treated hypertension accelerates CKD progression and increases cardiovascular morbidity.

Primary glomerulonephritides cause approximately 10-15% of CKD in developed nations, with significant geographic variation. Major entities include:

Chronic obstruction of urine flow (from stones, tumors, benign prostatic hyperplasia, or congenital anomalies) leads to tubular atrophy, interstitial fibrosis, and CKD. Vesicoureteral reflux (VUR) with recurrent pyelonephritis, particularly when starting in childhood, causes reflux nephropathy with blunted renal scarring and progressive CKD, though risk depends on grade of reflux and presence of infection.

Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in PKD1 (chromosome 16, ~85% of cases) or PKD2 (chromosome 4, ~15% of cases), is the most common inherited kidney disease affecting ~1:400 to 1:4000 people. Progressive cyst formation and expansion cause nephron loss; median age at ESRD is ~57 years for PKD1 and ~79 years for PKD2. Risk factors for more rapid progression include male gender, hypertension, proteinuria, and larger baseline kidney volume. Autosomal recessive polycystic kidney disease (ARPKD), caused by PKHD1 mutations, typically presents in infancy with severe kidney disease.

Chronic tubulointerstitial inflammation and fibrosis causes CKD through direct tubular and interstitial damage. Major causes include:

Systemic diseases cause glomerular injury superimposed on primary renal disease:

-

The typical stem: an adult over 55 with 10+ years of type 2 diabetes and hypertension, or a Black patient with long-standing hypertension, incidentally found to have a rising creatinine and albuminuria on routine labs. Early CKD (G1–G3a) is asymptomatic — symptoms track uremic toxin accumulation and appear largely at G4–G5.

Etiology-specific clues: flank pain with palpable bilateral abdominal masses and hematuria in ADPKD; hearing loss with hematuria in Alport syndrome; obstructive urinary symptoms in an older man with BPH-related obstructive nephropathy.

Step 2 — prove chronicity (≥3 months): repeat eGFR and UACR after at least three months, or find old labs. Features favoring CKD over AKI: normocytic anemia, hyperphosphatemia with hypocalcemia, secondary hyperparathyroidism, and small echogenic kidneys with loss of corticomedullary differentiation on ultrasound. Kidneys stay normal-sized or enlarged in diabetic nephropathy, HIV-associated nephropathy, amyloidosis, and ADPKD.

Step 4 — define the cause: renal ultrasound in all; serologies (ANA, ANCA, anti-GBM, complements, hepatitis B/C, HIV, SPEP/free light chains) when the picture is not clearly diabetic or hypertensive. Kidney biopsy is the gold standard for glomerular etiology but is generally avoided once kidneys are small and fibrotic, since it yields only end-stage scarring.

Immediate priorities: treat life-threatening hyperkalemia (IV calcium gluconate to stabilize myocardium, then insulin with dextrose and a beta-2 agonist to shift, then removal), decompensated volume overload (IV loop diuretic; thiazides lose potency at low GFR but add synergy), and severe uremia. Stop nephrotoxins: NSAIDs, aminoglycosides, and unnecessary iodinated contrast.

Risk-factor targets: ADA advises individualized A1c near 7% in most; metformin is contraindicated below eGFR 30. KDIGO 2021 BP guidance targets systolic <120 mmHg by standardized office measurement; ACC/AHA 2017 uses <130/80. Statin (or statin/ezetimibe) is recommended by KDIGO in nondialysis CKD patients ≥50 years; statins are not initiated de novo in dialysis patients.

Complication-directed therapy: oral sodium bicarbonate for metabolic acidosis; dietary phosphate restriction then a non-calcium binder (sevelamer) and active vitamin D or cinacalcet for secondary hyperparathyroidism; iron repletion before an erythropoiesis-stimulating agent, never targeting a normal hemoglobin; potassium binders (patiromer, sodium zirconium cyclosilicate) to preserve RAAS therapy. Hepatitis B and pneumococcal vaccination per ACIP.

Definitive therapy: dialysis is started for uremic pericarditis, encephalopathy, refractory hyperkalemia, acidosis, or volume overload — by symptoms, not by an eGFR number. Refer early for arteriovenous fistula creation and for preemptive transplant evaluation, which offers the best survival.